Robbins arroyo llp is investigating the officers and directors of solid biosciences inc. (sldb) on behalf of shareholders

San diego & cambridge, mass.--(business wire)--shareholder rights law firm robbins arroyo llp is investigating whether certain officers and directors of solid biosciences inc. (nasdaqgs: sldb) breached their fiduciary duties to shareholders. on march 14, 2018, solid biosciences announced that it received notification from the u.s. food and drug administration that the company's phase i/ii clinical trial for sgt-001 microdystrophin gene transfer in duchenne muscular dystrophy had been placed on clinical hold. since the disappointing news was announced, solid biosciences' stock has fallen over 67% to close at $8.50 per share on march 26, 2018—47% below the company's january 26, 2018 initial public offering price of $16 per share. view this press release on the firm's shareholder rights blog: www.robbinsarroyo.com/solid-biosciences-inc solid biosciences express shareholders have legal options concerned shareholders who would like more information about their rights and potential remedies can contact attorney leonid kandinov at (800) 350-6003, lkandinov@robbinsarroyo.com, or via the shareholder information form on the firm's website. robbins arroyo llp is a nationally recognized leader in shareholder rights law. the firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. attorney advertising. past results do not guarantee a similar outcome.
SLDB Ratings Summary
SLDB Quant Ranking